These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9520369)

  • 1. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase.
    Kwon HJ; Owa T; Hassig CA; Shimada J; Schreiber SL
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3356-61. PubMed ID: 9520369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and cellular characterization of the detransformation agent, (-)-depudecin.
    Shimada J; Kwon HJ; Sawamura M; Schreiber SL
    Chem Biol; 1995 Aug; 2(8):517-25. PubMed ID: 9383455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel compound, depudecin, induces production of transformation to the flat phenotype of NIH3T3 cells transformed by ras-oncogene.
    Sugita K; Yoshida H; Matsumoto M; Matsutani S
    Biochem Biophys Res Commun; 1992 Jan; 182(1):379-87. PubMed ID: 1731795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-parasitic activity of depudecin on Neospora caninum via the inhibition of histone deacetylase.
    Kwon HJ; Kim JH; Kim M; Lee JK; Hwang WS; Kim DY
    Vet Parasitol; 2003 Mar; 112(4):269-76. PubMed ID: 12623206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depudecin: a novel compound inducing the flat phenotype of NIH3T3 cells doubly transformed by ras- and src-oncogene, produced by Alternaria brassicicola.
    Matsumoto M; Matsutani S; Sugita K; Yoshida H; Hayashi F; Terui Y; Nakai H; Uotani N; Kawamura Y; Matsumoto K
    J Antibiot (Tokyo); 1992 Jun; 45(6):879-85. PubMed ID: 1500354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.
    Kijima M; Yoshida M; Sugita K; Horinouchi S; Beppu T
    J Biol Chem; 1993 Oct; 268(30):22429-35. PubMed ID: 8226751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosynthesis and role in virulence of the histone deacetylase inhibitor depudecin from Alternaria brassicicola.
    Wight WD; Kim KH; Lawrence CB; Walton JD
    Mol Plant Microbe Interact; 2009 Oct; 22(10):1258-67. PubMed ID: 19737099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depudecin, a microbial metabolite containing two epoxide groups, exhibits anti-angiogenic activity in vivo.
    Oikawa T; Onozawa C; Inose M; Sasaki M
    Biol Pharm Bull; 1995 Sep; 18(9):1305-7. PubMed ID: 8845831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trichostatin A-induced detransformation correlates with decreased focal adhesion kinase phosphorylation at tyrosine 861 in ras-transformed fibroblasts.
    Lim Y; Han I; Kwon HJ; Oh ES
    J Biol Chem; 2002 Apr; 277(15):12735-40. PubMed ID: 11821402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel tetracyclic peptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells.
    Yoshida H; Sugita K
    Jpn J Cancer Res; 1992 Apr; 83(4):324-8. PubMed ID: 1506265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts.
    Chen JS; Faller DV
    J Cell Physiol; 2005 Jan; 202(1):87-99. PubMed ID: 15389542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of the tumor suppressor C-terminal Src kinase (Csk)-binding protein (Cbp)/PAG1 is mediated by epigenetic histone modifications via the mitogen-activated protein kinase (MAPK)/phosphatidylinositol 3-kinase (PI3K) pathway.
    Suzuki K; Oneyama C; Kimura H; Tajima S; Okada M
    J Biol Chem; 2011 May; 286(18):15698-706. PubMed ID: 21388951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.
    Furumai R; Komatsu Y; Nishino N; Khochbin S; Yoshida M; Horinouchi S
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):87-92. PubMed ID: 11134513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Retention of Gene Functions in a Secondary Metabolite Cluster.
    Reynolds HT; Slot JC; Divon HH; Lysøe E; Proctor RH; Brown DW
    Mol Biol Evol; 2017 Aug; 34(8):2002-2015. PubMed ID: 28460114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase as a new target for cancer chemotherapy.
    Yoshida M; Furumai R; Nishiyama M; Komatsu Y; Nishino N; Horinouchi S
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S20-6. PubMed ID: 11587361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosynthesis of depudecin, a metabolite of Nimbya scirpicola.
    Tanaka M; Fujimori T; Nabeta K
    Biosci Biotechnol Biochem; 2000 Feb; 64(2):244-7. PubMed ID: 10737176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.
    Munshi A; Kurland JF; Nishikawa T; Tanaka T; Hobbs ML; Tucker SL; Ismail S; Stevens C; Meyn RE
    Clin Cancer Res; 2005 Jul; 11(13):4912-22. PubMed ID: 16000590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts.
    Brinkmann H; Dahler AL; Popa C; Serewko MM; Parsons PG; Gabrielli BG; Burgess AJ; Saunders NA
    J Biol Chem; 2001 Jun; 276(25):22491-9. PubMed ID: 11304533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depudecin makes a debut.
    Privalsky ML
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3335-7. PubMed ID: 9520362
    [No Abstract]   [Full Text] [Related]  

  • 20. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.
    Marks PA; Richon VM; Rifkind RA
    J Natl Cancer Inst; 2000 Aug; 92(15):1210-6. PubMed ID: 10922406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.